Welcome to the Oncology Brothers podcast! In this episode, we were joined by Thomas LeBlanc, MD MA, from the Duke Cancer Institute to discuss the treatment algorithm for myelodysplastic syndrome (MDS).

We dived deep into the importance of risk stratification in MDS, exploring lower-risk, intermediate-risk, and higher-risk categories. Dr. LeBlanc shared insights on the role of next-generation sequencing (NGS) and the Revised International Prognostic Scoring System (IPSS-R) in guiding treatment decisions.

Key topics included:

Treatment options for lower-risk MDS, including the use of erythropoiesis-stimulating agents (ESAs) and luspatercept
The significance of ring sideroblasts and del(5q) in treatment selection
The management of anemia, thrombocytopenia, and neutropenia in MDS patients
The emerging role of imetelstat for heavily transfusion-dependent patients and its unique side effects

Join us as we unpacked the complexities of MDS treatment and emphasize the importance of personalized care for patients.

Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more insightful discussions in oncology!

#MDS, #MyelodysplasticSyndrome, #RiskStratification, #OncologyBrothers

Treatment Algorithm of Myelodysplastic Syndrome (MDS) in 2026 - Dr. Thomas LeBlanc

Oncology Brothers: Practice-Changing Cancer Discussions

Treatment Algorithm of Myelodysplastic Syndrome (MDS) in 2026 - Dr. Thomas LeBlanc